Aridis Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• AR-301 · Infectious Disease
  AR-301 is a monoclonal antibody that targets and neutralizes Pseudomonas aeruginosa exotoxin A to reduce bacterial virulence and enhance immune clearance in respiratory infections.

Phase 1 pipeline

• KBSA301

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aridis Pharmaceuticals, Inc. portfolio CI brief
• Aridis Pharmaceuticals, Inc. pipeline updates RSS